<DOC>
	<DOCNO>NCT00927966</DOCNO>
	<brief_summary>The purpose research study determine safety combination RAD001 CP-751,871 , well high dose combination give people safely . RAD001 newly discover drug may stop cancer cell grow abnormally . This drug extensively study many cancer . In particular , show effective slow growth kidney cancer . CP-751,871 another newly discover drug may stop tumor growth . It currently study wide variety cancer , information research study suggest two drug combination may help stop cancer growth .</brief_summary>
	<brief_title>RAD001 Combination With CP-751,871 Patients Wtih Advanced Sarcomas Other Malignant Neoplasms</brief_title>
	<detailed_description>- In research study , `` cycle '' study drug dose last 21 day . In first cycle , participant come clinic Days 1 , 8 , 15 . During cycle 2 4 , participant come clinic Days 1 8 . The rest clinic visit occur Day 1 every cycle thereafter . - During cycle , participant take RAD001 orally , day morning . In addition , participant receive CP-751,871 intravenously every cycle first day cycle . - Since look high dose study drug administer safely without severe unmanageable side effect , everyone participates research study receive dose study drug . The dose depend number participant enrol study well tolerated dos . - Participants may remain research study long serious side effect diseae get bad .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm advanced sarcoma advance malignant solid tumor know curative therapy exists . Patients must prior progression , intolerance refuse approved standard therapy prove prolong life . Measurable disease per RECIST . A lesion previously irradiate area eligible consider measurable disease long objective evidence progression lesion prior study enrollment 18 year age old ECOG Performance Status 01 Participants must normal organ marrow function outline protocol Fully recover acute effect prior cancer therapy initiation study drug Negative urine serum pregnancy test within 7 day prior initiation study drug woman childbearing potential Women childbearing potential men must agree use adequate contraception prior study entry 6 month last dose study drug Participants gastrointestinal tumor ( GIST ) approve tyrosine kinase inhibitor within 2 week prior study entry All participant systemic anticancer therapy within 3 week ( 8 week nitrosoureas mitomycin C ) prior study entry Participants radiotherapy and/or major surgery within 2 week prior study entry Concurrent use anticancer therapy , study agent , growth hormone , growth hormone inhibitor aminoglycoside antibiotic Participants chronic high dose immunosuppressive steroid therapy within 2 week prior enrollment . Previous high dose steroid treatment &gt; 2 week prior study entry , topical inhale corticosteroid allow Presence symptomatic uncontrolled brain central nervous system metastases History allergic reaction attribute compound similar chemical biologic composition RAD001 and/or CP751,871 Participants receive medication substance inhibitor inducer CYP3A Uncontrolled diabetes Bleeding diathesis requirement therapeutic anticoagulation Uncontrolled intercurrent illness Pregnant nursing woman HIV positive individual combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>RAD001</keyword>
	<keyword>CP-751,871</keyword>
	<keyword>advanced sarcoma</keyword>
	<keyword>advanced malignant solid tumor</keyword>
</DOC>